Urinary Incontinence, Urge: Clinical Trials

26 trials for Urinary Incontinence, Urge, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 5 terminated, 2 withdrawn, 1 unknown. 26 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 326Completed 18, Terminated 5, Withdrawn 2, Unknown 1
Phase 21Terminated 1

Follow Urinary Incontinence, Urge: new trials by email Literature Review of Urinary Incontinence, Urge trials Research Report on Urinary Incontinence, Urge

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
Alkalinized Lidocaine, Placebo Sodium Chloride 0.9% Inj - Urge Incontinence, Overactive Bladder
Phase 3UnknownHerlev and Gentofte Hospital502022-09-122022-09-22
Sling vs Botox for Mixed Incontinence
Botox® injection, Mid-urethral sling - Urinary Incontinence, Stress, Urinary Incontinence, Urge
Phase 3CompletedNICHD Pelvic Floor Disorders Network1502020-06-082025-06-03
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
Vibegron, placebos, Tolterodine Tartrate ER - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH5062018-06-142021-03-18
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
vibegron, Vibegron placebo, Tolterodine Tartrate ER - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH15302018-03-262021-03-04
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Uritos®, Urotol® - Overactive Bladder
Phase 3CompletedR-Pharm3002016-07-182019-05-21
Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder
Bryophyllum - Overactive Bladder, Urge Urinary Incontinence
Phase 2 / Phase 3TerminatedUniversity of Zurich92014-05-012017-10-26
Combined Treatment for Mixed Incontinence
Miduretheral Sling, Miduretheral Sling with behavioral/pelvic floor therapy - Urinary Incontinence, Stress, Urinary Incontinence, Urge
Phase 3CompletedNICHD Pelvic Floor Disorders Network4802013-10-282020-05-14
Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
Fesoterodine Fumarate - Urge Urinary Incontinence
Phase 3CompletedUniversity of North Carolina, Chapel Hill612012-09-012020-03-18
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
InterStim® device, Botox® injection - Urinary Incontinence, Urge
Phase 3CompletedNICHD Pelvic Floor Disorders Network3862012-02-012018-05-02
Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder
Electrical Field Stimulation Device, Sham Nerve Stimulation Device - Urinary Incontinence, Urge
Phase 3TerminatedEMKinetics, Inc1302011-10-012013-01-31
Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence
Transcutaneous mechanical nerve stimulation - Stress Urinary Incontinence, Urge Urinary Incontinence
Phase 3TerminatedCopenhagen University Hospital at Herlev42011-05-012013-05-24
Anticholinergic vs. Botox Comparison Study
Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg - Urge Urinary Incontinence, Overactive Bladder
Phase 3CompletedNICHD Pelvic Floor Disorders Network2492010-03-012018-05-02
Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
Propiverine Hydrochloride, Tolterodine Extended-release Tablet - Overactive Bladder
Phase 3CompletedLee's Pharmaceutical Limited3242010-01-012012-01-25
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
YM178, Placebo, tolterodine ER - Urinary Bladder, Overactive
Phase 3CompletedAstellas Pharma Inc11262009-12-212024-10-31
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
YM178, Placebo, tolterodine - Urinary Bladder, Overactive
Phase 3CompletedAstellas Pharma Inc11392009-07-242024-10-31
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Oxybutynin, Placebo - Urge Urinary Incontinence, Urinary Frequency
Phase 3CompletedAntares Pharma Inc.6262009-03-012014-07-02
Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence
Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark) - Urinary Incontinence
Phase 3WithdrawnCopenhagen University Hospital at Herlev2008-08-012012-02-24
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Mirabegron, Tolterodine, Placebo to Mirabegron - Urinary Bladder, Overactive
Phase 3CompletedAstellas Pharma Inc23362008-04-282024-11-20
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Mirabegron, Tolterodine, Placebo to Mirabegron - Urinary Bladder, Overactive
Phase 3CompletedAstellas Pharma Inc27922008-04-252024-11-20
Over Active Bladder Instillation Study - Botox
Botox Instillation, DMSO Instillation - Overactive Bladder, Urinary Urge Incontinence
Phase 3TerminatedMayo Clinic252008-04-012014-07-11

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Urinary Bladder, Overactive (18)  ·  Urinary Incontinence (11)  ·  Urinary Incontinence, Stress (4)  ·  Lower Urinary Tract Symptoms (2)  ·  Urologic Diseases (2)  ·  Hematuria (1)  ·  Pain, Procedural (1)  ·  Urinary Tract Infections (1)

Broader conditions

Female Urogenital Diseases (26)  ·  Female Urogenital Diseases and Pregnancy Complications (26)  ·  Male Urogenital Diseases (26)  ·  Pathological Conditions, Signs and Symptoms (26)  ·  Signs and Symptoms (26)  ·  Urination Disorders (26)  ·  Urogenital Diseases (26)  ·  Urological Manifestations (26)  ·  Lower Urinary Tract Symptoms (24)  ·  Urologic Diseases (24)  ·  Urinary Bladder Diseases (18)  ·  Urinary Incontinence (15)  ·  Hemorrhage (1)  ·  Infections (1)  ·  Neurologic Manifestations (1)

Interventions

Tolterodine Tartrate (9)  ·  Botulinum Toxins, Type A (5)  ·  mirabegron (5)  ·  oxybutynin (3)  ·  N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (2)  ·  ritobegron ethyl (2)  ·  Dimethyl Sulfoxide (1)  ·  Solifenacin Succinate (1)  ·  Suburethral Slings (1)  ·  fesoterodine (1)  ·  imidafenacin (1)  ·  propiverine (1)  ·  trospium chloride (1)

Sponsors

Astellas Pharma Inc (5)  ·  NICHD Pelvic Floor Disorders Network (4)  ·  Copenhagen University Hospital at Herlev (2)  ·  Kissei Pharmaceutical Co., Ltd. (2)  ·  Urovant Sciences GmbH (2)  ·  Alza Corporation, DE, USA (1)  ·  Antares Pharma Inc. (1)  ·  EMKinetics, Inc (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Herlev and Gentofte Hospital (1)  ·  Lee's Pharmaceutical Limited (1)  ·  Mayo Clinic (1)  ·  R-Pharm (1)  ·  University of North Carolina, Chapel Hill (1)  ·  University of Zurich (1)

Countries

United States (14)  ·  Denmark (5)  ·  Canada (3)  ·  Hungary (3)  ·  Japan (3)  ·  Latvia (3)  ·  Lithuania (3)  ·  Poland (3)  ·  Russia (3)  ·  Switzerland (3)  ·  Australia (2)  ·  Austria (2)  ·  Belarus (2)  ·  Belgium (2)  ·  China (2)

Top investigators

Yasuhiro Omori (2)  ·  Anthony Visco, MD (1)  ·  Benjamin Li, PhD (1)  ·  Cindy Amundsen, MD (1)  ·  Deborah L. Myers, MD (1)  ·  Dennis Wallace (1)  ·  Dennis Wallace, PhD (1)  ·  Heidi S Harvey, MD (1)  ·  Holly Richter, PhD, MD (1)  ·  Jennifer M Wu, MD (1)  ·  Jens R Sonksen, MD, Ph.D (1)  ·  Jerry Lowder, MD (1)

Results publications

PMID 37160401, PMID 24246044, PMID 33620895, PMID 18499184, PMID 19233423, PMID 22008247, PMID 23036134, PMID 23218404, PMID 24486637, PMID 26516810, PMID 27564385, PMID 29031894, PMID 31211964, PMID 31529007, PMID 31895722, PMID 32769647, PMID 33332699, PMID 33356445, PMID 33469832, PMID 34237755, PMID 34242627, PMID 34297969, PMID 34921665, PMID 35685566, PMID 36384907, PMID 37586052, PMID 37586057, PMID 38212101, PMID 38651909, PMID 39797697, PMID 40323617

NIH funding

2017 (2), U01HD069031 (2), U10HD041261 (2), U10HD041267 (2), U10HD054214 (2), U10HD054215 (2), R03AG042335 (1), U01HD041249 (1), U10HD041250 (1), U10HD041263 (1), U10HD054136 (1), U10HD054241 (1), U10HD069010 (1), U10HD069013 (1), U10HD069025 (1)